Adma Biologics (ADMA) Cash from Operations Growth (1y) (2012 - 2025)
Adma Biologics (ADMA) Cash from Operations Growth (1y) (2012 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
85.14% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-15.72% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
74.39% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Adma Biologics |
1.98 Bn |
1.89 Bn |
88.82 Mn |
-29.03% |
| Date | Value |
|---|
| Dec 31, 2025 |
-29.03% |
| Sep 30, 2025 |
-46.89% |
| Jun 30, 2025 |
-53.69% |
| Mar 31, 2025 |
-787.06% |
| Dec 31, 2024 |
185.37% |
| Sep 30, 2024 |
108.83% |
| Jun 30, 2024 |
853.36% |
| Mar 31, 2024 |
84.94% |
| Dec 31, 2023 |
338.47% |
| Sep 30, 2023 |
190.22% |
| Jun 30, 2023 |
52.78% |
| Mar 31, 2023 |
43.40% |
| Dec 31, 2022 |
77.95% |
| Sep 30, 2022 |
0.95% |
| Jun 30, 2022 |
60.23% |
| Mar 31, 2022 |
21.72% |
| Dec 31, 2021 |
-3.87% |
| Sep 30, 2021 |
43.77% |
| Jun 30, 2021 |
-51.58% |
| Mar 31, 2021 |
-34.82% |
